ZFAND2B

Across TCGA pan-cancer cohorts, ZFAND2B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZFAND2B data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZFAND2B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZFAND2B expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, PDAC, and UCEC are the cancer types where ZFAND2B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	1.000	0.318	.003	26	view →
PDAC	OS	Median	III,IV	0.496	0.935	.015	14	view →
UCEC	DFS	Tertile	All	0.970	0.742	.005	12	view →
LUAD	DFS	Tertile	All	0.929	0.507	.008	5	view →
CCRCC	OS	Median	II,III,IV	0.970	0.844	.039	2	view →
LSCC	DFS	Median	III,IV	0.507	0.844	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZFAND2B–HNSC (DFS)

Open the HNSC breakdown →